Mesa Laboratories Inc 2027 Q1 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Mesa Laboratories reported first quarter fiscal year 2027 revenue of $60.1 million, a 1% increase compared to the prior year, with core organic revenue growth of 0.4%.
- Biopharmaceutical Development (BPD) grew 5% organically this quarter, recovering from a nearly 30% decline the prior quarter.
- Calibration Solutions grew 7.6% organically year over year, continuing steady growth.
- Single-Use Consumables (SDC) revenue declined 3.6% year over year this quarter due to delivery reliability issues, but grew about 5% on a trailing 12-month basis.
- Clinical Genomics revenue was essentially flat, declining 0.1%, with China down 7% and other regions up 0.6%.
- Adjusted operating income excluding unusual items was approximately $66 million on a trailing 12-month basis, up about $2.5 million from fiscal 2026 year-end.
- Gross profit margin improved by roughly 290 basis points to 64.9%, driven by supply chain efficiencies and favorable product mix, partially offset by lower SDC volumes.
- Operating expenses declined 5.6% to $32 million due to lower stock-based compensation and cost discipline despite increased investment in SDC sales and marketing.
- GAAP operating income increased 129% to $7 million, and non-GAAP adjusted operating income increased 16.5% to $15 million or $2.61 per diluted share.
- Net leverage ratio improved to 1.85 times after repaying $8.7 million of debt during the quarter.
- GAAP net income was $2.8 million or $0.49 per diluted share, down 40.3% due to non-operating expense swings from foreign currency effects, not operations.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Afternoon, and thank you for joining us to discuss Mesa Laboratories' first quarter 2027 earnings call. At this time, all participants are in listen-only mode. A replay of this webcast will also be made available on our website after the call. Following our prepared remarks, we will open the line for questions. To ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. If anyone should require operator assistance during the conference, please press star zero. As a reminder, this conference is being recorded. Our speakers today are Siddhartha Kadia, President and Chief Executive Officer, John Sakys, Vice President and Chief Financial Officer, and Doug Ferrell, Investor Relations. It is now my pleasure to introduce Doug Ferrell. Thank you. Mr. Ferrell, you may begin.
Please be advised that our remarks today, including answers to your questions, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements include those relating to future financial and operational results, future taxes, future strategic and operational initiatives, new products, and our future net leverage ratio. Words such as seek, expect, plan, intend, anticipate, believe, could, should, estimate, may, project, and target, and similar expressions may also identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those currently anticipated.
Those include risks relating to market acceptance of and demand for our products, our ability to execute on strategic, commercial, and operational initiatives and achieve the anticipated benefits from those initiatives, potential issues relating to our manufacturing, fulfillment, supply chain performance, possible changes in customer purchasing patterns, the development and success of new products and product launches, regulatory matters, the effect on our business of capital allocation decisions and debt reduction initiatives, expected tax rates, national and global economic conditions, and other factors described in our filings with the Securities and Exchange Commission, which are incorporated by reference. We disclaim any obligation to update these forward-looking statements. In addition, we will provide certain non-GAAP financial information in this call, including adjusted operating income on a trailing 12-month basis.
The relevant definitions and GAAP reconciliations may be found in our earnings release and the supplemental reconciliation posted on the investor relations section of our website at mesalabs.com. With that, let me turn the call over to Mesa's CEO, Siddhartha Kadia.
Thank you, and good afternoon, everyone. This is my first earnings call as Mesa's CEO, and I want to use it the way I intend to use every call going forward, to be direct with you about what's working, what's not yet working, and what I have decided to do about it. I've learned a lot in my first 100 days, and I'm excited about what I've found. Excited enough that I wanted to talk with you earlier than we had originally planned. We had committed to a first call alongside our second quarter results this fall. I didn't want to wait that long. So because it is early, think of today as the appetizer, not the dinner. Dinner comes in the fall at our next earnings call when I put full year guidance in front of you alongside first half results.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring